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High-Dose IL-2 Skews a Glucocorticoid-Driven IL-17+IL-10+
Memory CD4+ T Cell Response towards a Single
IL-10–Producing Phenotype
Elizabeth H. Mann,*,† Leona Gabryšova´,† Paul E. Pfeffer,*,‡ Anne O’Garra,†,x and
Catherine M. Hawrylowicz*
Glucocorticoids are known to increase production of the anti-inflammatory cytokine IL-10, and this action is associated with their
clinical efficacy in asthmatics. However, glucocorticoids also enhance the synthesis of IL-17A by PBMCs, which, in excess, is as-
sociated with increased asthma severity and glucocorticoid-refractory disease. In this study, we show that the glucocorticoid dexa-
methasone significantly increased IL-10 production by human memory CD4+ T cells from healthy donors, as assessed by
intracellular cytokine staining. In addition, dexamethasone increased production of IL-17A, IL-17F, and IL-22, with the most
striking enhancement in cells coproducing Th17-associated cytokines together with IL-10. Of note, an increase in IFN-g+IL-10+
cells was also observed despite overall downregulation of IFN-g production. These dexamethasone-driven IL-10+ cells, and
predominantly the IL-17+IL-10+ double-producing cells, were markedly refractory to the inhibitory effect of dexamethasone
on proliferation and IL-2Ra expression, which facilitated their preferential IL-2–dependent expansion. Although lower concen-
trations of exogenous IL-2 promoted IL-10+ cells coproducing proinflammatory cytokines, higher IL-2 doses, both alone and in
combination with dexamethasone, increased the proportion of single IL-10+ T cells. Thus, glucocorticoid-induced IL-10 is only
accompanied by an increase of IL-17 in a low IL-2 setting, which is, nevertheless, likely to be protective owing to the induction of
regulatory IL-17+IL-10+–coproducing cells. These findings open new avenues of investigation with respect to the role of IL-2 in
glucocorticoid responsiveness that have potential implications for optimizing the benefit/risk ratio of glucocorticoids in the clinic.
The Journal of Immunology, 2019, 202: 000–000.
G
lucocorticoids are a class of lipophilic steroid hormones
that are synthesized endogenously by the adrenal cortex.
They can bind to the glucocorticoid receptor (GR),
which is expressed by most nucleated cells, and trigger a broad
range of effects via transactivation and transrepression in addition
to other GR-independent actions. Their actions are pleiotropic,
affecting various physiological processes including development,
metabolism, and inflammation, and, as such, synthetic glucocor-
ticoids have been used in the clinic since 1948 (1). Glucocorticoids
remain the most important anti-inflammatory pharmacotherapy
in modern medicine despite their untoward side effects. Their
anti-inflammatory properties result from their transrepression of
proinflammatory genes such as IL-1b and IL-4, transactivation of
anti-inflammatory genes, and upregulation of the frequency and ac-
tivity of regulatory T cells (Tregs) (2). In vivo glucocorticoids have
been shown to increase serum levels of the anti-inflammatory cyto-
kine IL-10 (3) as well as the synthesis of IL-10 by cells locally in the
airways (4). Furthermore, the synthetic glucocorticoid dexamethasone
enhances the concentration of IL-10 in cultures of PBMCs, CD4+,
and CD8+ T cells isolated from healthy humans in vitro (5–8).
The importance of glucocorticoid-induced IL-10 is highlighted
by studies in patients with severe steroid-resistant (SR) asthma,
who represent a profound clinical challenge for disease manage-
ment. SR asthma patients have a defect in the dexamethasone-
driven IL-10 response (6, 9, 10) and heightened levels of
IL-17A; indeed, levels of IL-17A inversely correlate with lung
function (11) and are significantly elevated in the peripheral blood
(6, 7, 12), sputum (13), serum (14, 15), and bronchial alveolar lining
fluid (16, 17) of patients with severe asthma, with the greatest levels
observed in patients with SR disease (7). Levels of IL-17A are also
elevated in mouse models of airway hyperresponsiveness in which
Th17 cells drive pathological conditions (18, 19).
Th17 cells are critical for protecting against mucosal and fungal
infections; however, they have also been implicated in various
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immune-mediated diseases (20). More specifically, cells that differ-
entiate in the presence of IL-23 and TGF-b3 to coexpress Th1- and
Th17-associated molecules have been shown to drive experimental
autoimmune encephalomyelitis in mice (21, 22). Ramesh et al. (23)
showed that human peripheral blood CD4+ T cells cultured with
IL-23 produced IL-17A, IL-17F, IL-22, and IFN-g, but not IL-10.
However, distinct Th17 phenotypes exist; for example, Zielinski
et al. (24) observed Candida albicans–specific human CD4+ T cells
producing IL-17A and IFN-g, but not IL-10, and Staphylococcus
aureus–specific cells that, in contrast, could produce IL-10. Func-
tionally, Th17 cells that coproduce IL-10 have been shown to
restrain Th17 cell–mediated pathological conditions (21, 25–27).
To better understand these seemingly opposing effects of
glucocorticoids on the induction of IL-10 and IL-17A, this study
sought to characterize the cellular source of glucocorticoid-driven
IL-10 and investigate its coexpression with other cytokines based
on emerging data of functionally distinct Th17 subsets. We set out to
dissect the mechanism for induction of IL-10 versus IL-17 in T cells,
which are critical targets in inflammatory tissues such as the airways
in asthma. This study identifies that glucocorticoids enhance the
proportion of memory CD4+ T cells that coproduce IL-17+IL-10+,
which is reflective of a less inflammatory, protective Th17 pheno-
type. Notably, addition of higher dose exogenous IL-2 skews this
response toward a single IL-10–producing phenotype, which has
potential implications for generating more targeted therapeutics.
Materials and Methods
Cell isolation and culture
Ethical approval was granted by London Bridge National Research Ethics
Service Ethics Committee (REC 09/H0804/77 and REC 14/LO/16990),
Human Tissue Act license number 12650 at the Francis Crick Institute,
and full written informed consent obtained from all donors. Peripheral
venous blood was collected from nonasthmatic male and female healthy
adults into syringes containing sodium citrate (10:1). PBMCs were isolated
using Lymphoprep as previously described (8). CD45RO+ memory CD4+
T cells were purified by negative selection (.97% CD4+CD45RO+;
Miltenyi Biotec, Bisley, U.K.). Cells were resuspended at a concentration
of 1 3 106 cells/ml in RPMI 1640 growth medium containing 10% FBS,
2 mM L-glutamine, and 50 mg/ml gentamicin.
A total of 0.5 3 106 cells were stimulated with 1 mg/ml plate-bound
anti-CD3 (clone OKT-3) and 50 IU/ml recombinant human IL-2 (rhIL-2)
(EuroCetus, Harefield, U.K.) for 5 d, unless otherwise stated, in a 48-well
plate at 37˚C (5% CO2). On day 3, half of the supernatant was removed
and replaced with full media supplemented with rhIL-2. One hundred
nanomolars of dexamethasone (Sigma-Aldrich, Gillingham, U.K.) or
0.01% ethanol vehicle control was added to the cell cultures where indi-
cated. Ten micrograms per milliliter anti–IL-2 (clone 5334; R&D Systems)
was added on days 0 and 3 where indicated.
Cell proliferation
Prior to culture, cells were labeled with 1 mM CellTrace Violet as per the
manufacturer’s instructions (Thermo Fisher Scientific). Cell proliferation
was assessed by loss of fluorescence intensity on an NxT Attune (Thermo
Fisher Scientific) or Fortessa (BD Biosciences).
Surface staining
Cells were harvested and washed in 2% FCS/PBS prior to performing
viability (Zombie Violet/Zombie Aqua viability dye [Life Technologies])
and surface staining on ice in the dark for 30 min. The following Abs were
used for cell surface phenotyping: CD4/PerCP/Cy5.5, CD45RA/APCCy7,
CD45RO/PECy7 (clones OKT-4, HI100, and UCHL1, respectively; Bio-
Legend), CD3/V500 and CD25/APCH7 (clones SP34-2 and M-A251, re-
spectively; BD Biosciences), and CD122/FITC (TU27; eBiosciences). Cells
were washed a further two times in 2% FCS/PBS and then fluorescence was
assessed using an NxT Attune or Fortessa.
Intracellular staining
Human cells were stimulated with 5 ng/ml PMA and 500 ng/ml ionomycin
(Sigma-Aldrich) for 4 h at 37˚C, with 2 mM monensin added for the final
3 h. Cells were surface stained on ice with the relevant markers and Zombie
Aqua viability dye (BioLegend) for 30 min before fixing and permeabilizing
using BD Cytofix/Cytoperm Kit as per the manufacturer’s instructions. The
following Abs were used to stain intracellular molecules: IL-22/PECy7
(22URTI), IL-22/PE (22URTI), IL-4/PECy7 (8D4-8), IL-17A/APC (eBio64-
Dec17), IL-17F/aF488 (Poly5166), and IL-2/PerCP/Cy5.5 (MQ1-17H12), all
from eBiosciences; IFN-g/FITC (4S.B3) and IL-10/PE (JEs3-9D7) from BD
Biosciences. Cells were washed a further two times in 2% FCS/PBS and then
fluorescence was assessed using an NxT Attune or Fortessa.
Phospho-STAT5 flow cytometry
Cells were rested in full media for 2 h and then stimulated with 5 ng/ml rhIL-2
for 30 min. Samples were then surface stained and fixed prior to resuspending
inBDPhosflowPermBuffer III. Samples were incubated in PermBuffer III on
ice for 30 min and then washed twice in Perm Buffer III before staining with
the phospho-STAT5Ab (Alexa Fluor 488; 47/Stat5 [pY694]; BDBiosciences)
for a further 30 min on ice. Cells were washed a further two times in 2% FCS/
PBS and then fluorescence was assessed using an NxT Attune or Fortessa.
Data analysis
Flow cytometry data were analyzed using FlowJo (version 10; Tree Star).
Singlet events (based on both forward and side scatter area and height
comparison) and viable (Zombie Aqua–negative) cells were selected prior
to analysis. Cumulative data analysis was performed in GraphPad Prism
version 7.00 for Mac OS X (GraphPad Software, San Diego, CA). After
assessing for a Gaussian distribution, an appropriate statistical test was
performed as described in the figure legends at the 95% confidence level.
Data are shown as mean 6 SEM.
Results
Dexamethasone increases production of IL-10 by human
memory CD4+ T cells
We have previously shown that the glucocorticoid dexamethasone
increases the concentration of IL-10 in the supernatants of anti–CD3/
IL-2–stimulated, CD8-depleted PBMC, CD4+ T cell, and CD8+
T cell cultures (5–8). To characterize which T cell subpopulation
showed the greatest induction of IL-10 expression by dexametha-
sone, PBMCs were stimulated with anti-CD3 and IL-2 T cell
stimulation in the absence or presence of 1027M dexamethasone.
Dexamethasone increased the frequency of IL-10–producing cells
to the greatest extent in the CD45RO+ memory compartment of
CD4+ PBMCs following 5 d stimulation, as assessed by intracel-
lular cytokine staining (Fig. 1A, 1B, Supplemental Fig. 1). Con-
sistent with this, in pure memory CD4+ T cell cultures, a greater
frequency of cells expressed IL-10, and this was dose dependently
upregulated by dexamethasone (Fig. 1C).
Dexamethasone enhances production of IL-10 and IL-17A but
not IFN-g or IL-4
The kinetics of the dexamethasone-driven IL-10 response was next
investigated directly in memory CD4+ T cells stimulated over a 6-d
culture period (Fig. 2). In the absence of dexamethasone, the fre-
quency of IL-10–producing cells reduced over time. In contrast, ad-
dition of 1027M dexamethasone significantly increased the frequency
of IL-10+ cells by day 5, although not at earlier time points. The
proportion of IL-17A+ cells gradually increased with time and
dexamethasone significantly, albeit more modestly, further enhanced
the frequency of IL-17A+ T cells on days 5 and 6 of culture (Fig. 2A).
In contrast, expression of IFN-g, IL-4, and IL-2 was reduced or
unaltered by dexamethasone throughout the culture (Fig. 2A, 2B).
These findings are in keeping with our previous findings (6, 7, 12)
and further demonstrate that memory CD4+ T cells are the cellular
source of both IL-10 and IL-17A following dexamethasone treatment.
Dexamethasone induces coproduction of IL-10 with multiple
proinflammatory cytokines
IL-10+CD4+ T cells can coproduce multiple other proinflammatory
cytokines in a heterogeneous manner (28), including IL-17A
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(21, 24–27). We, therefore, investigated the effect of dexametha-
sone on other Th17-associated cytokines, as well as the copro-
duction of cytokines with IL-10 by memory CD4+ T cells.
Dexamethasone enriched the proportion of memory CD4+ T cells
producing the Th17 family members IL-17F and IL-22 (Fig. 3A, 3B,
Supplemental Fig. 2A). The average fold change in IL-17A,
IL-17F, and IL-22 expression was 1.9-, 4.3-, and 1.4-fold re-
spectively, and that of IL-10+ cells was 4.9-fold, relative to the
vehicle control (Supplemental Fig. 2B). Notably greater fold in-
creases were consistently observed in cells coproducing IL-10
together with Th17-associated cytokines, as compared with their
IL-102 counterparts (Supplemental Fig. 2B). Dexamethasone
significantly reduced the frequency of IFN-g+ cells that did not
coproduce IL-10 but induced a 7.5-fold increase in the proportion
of IFN-g+IL-10+ memory CD4+ T cells, resulting in no change in
the overall proportion of IFN-g+ memory CD4+ T cells. A similar
trend was observed for production of IL-4 and IL-2 by
dexamethasone-treated memory CD4+ T cells, with an enhanced
proportion of cells coproducing IL-10 in contrast to a reduced
frequency of IL-102 cells.
Because it has been reported that inflammatory Th17 cells may
coproduce inflammatory cytokines such as IFN-g (21–23), the
dexamethasone-stimulated cells analyzed for IL-10 and IL-17A
production were further investigated for coproduction of IL-17F
(yellow), IL-22 (red), IFN-g (blue), IL-4 (green), and IL-2 (orange)
(Fig. 3C). As predicted, IL-17F (yellow) was predominantly pro-
duced by IL-17A+ cells, irrespective of whether they were IL-102
or IL-10+. Although IL-22+ cells (red) were present in both the
IL-10+ and IL-102 populations, most did not coproduce IL-17A.
The majority of IFN-g+ (blue) or IL-4+ (green) cells did not co-
produce IL-17A but many coexpressed IL-10. IL-2+ (orange) cells
were predominantly negative for IL-17A and IL-10 (Fig. 3C).
FIGURE 1. Glucocorticoids enhance production of
IL-10 in memory CD4+ T cells. PBMCs (A and B) or
memory CD4+ T cells (C) from healthy donors were
stimulated with 1 3 1029 to 1 3 1027M dexamethasone
(Dex) or control for 5 d. Cells were then stimulated for 4 h
with PMA and ionomycin prior to staining for surface
markers and intracellular IL-10. For PBMC cultures,
shown are representative plots (A) and cumulative data (B)
gating of CD4+CD45RO+ cells (n = 4); data assessed by a
paired t test. (C) The percentage of IL-10+ cells in memory
CD4+ T cell cultures (n = 9); data assessed by repeated
measures one-way ANOVA with Tukey multiple com-
parisons test. *p # 0.05, ****p # 0.0001.
FIGURE 2. Glucocorticoids increase expression of IL-10 and IL-17A, but not IFN-g, IL-4, or IL-2, in memory CD4+ T cell cultures. Memory CD4+
T cells were stimulated in the presence of vehicle control (gray) or 13 1027M dexamethasone (black; Dex). On the indicated day, cells were stimulated for
4 h with PMA and ionomycin to assess intracellular cytokine expression. Shown are cumulative data [(A); n = 4; except IL-4, n = 2] and representative plots
(B). Data assessed by a two-way ANOVA with Sidak multiple comparisons test. *p # 0.05, **p # 0.01, ***p # 0.001.
The Journal of Immunology 3









Therefore, dexamethasone dominantly drives the production of
IL-10 across all memory CD4+ T cell subsets, excluding those
producing IL-2. Notably, the dexamethasone-stimulated, IL-17A–
producing cells were predominantly negative for IFN-g, IL-4, and
IL-2, although a large proportion coproduced IL-10, which is in-
dicative of a nonpathogenic Th17 phenotype (21, 25–27).
IL-10+ cells are refractory to the suppressive effects of
dexamethasone on cell proliferation
To investigate the mechanisms driving the enrichment of IL-10+
cells within dexamethasone-treated memory CD4+ T cell
cultures, cytokine expression was assessed in relation to cell
proliferation. Memory CD4+ T cells were labeled with the
fluorescent dye CellTrace Violet prior to stimulation in the
presence or absence of dexamethasone. IL-10 and IL-17Awere
produced predominantly by cells that had undergone multiple
rounds of cell division (Fig. 4A) and were enhanced in the
presence of dexamethasone (Fig. 4A, 4B). In contrast, IFN-g
and IL-4 production was seen in both dividing and nondividing
cells, but their frequency was not altered by dexamethasone.
IL-2 was produced primarily by the undivided population and
was decreased by dexamethasone (Fig. 4A, 4B).
Glucocorticoids have been repeatedly shown to dampen T cell
proliferation (29), which we now show for total memory CD4+
T cells (“all cells,” Fig. 4C, 4D). However, cells producing IL-10
and/or IL-17A were refractory to this suppressive effect of dexa-
methasone on cell proliferation (Fig. 4C, 4D). This contrasts with
the proliferation of IFN-g+, IL-4+, and IL-2+ cells, which was
significantly reduced in dexamethasone-treated cultures (Fig. 4C,
4D). Notably, the proliferation of all IL-10+ memory CD4+
T cells, regardless of whether they coproduced IFN-g, IL-4, or
IL-2, was not suppressed by dexamethasone, in marked contrast to
their IL-102 counterparts (Fig. 4C, 4D). These data show that
IL-17A+ and IL-10+ cells are markedly refractory to the antiproliferative
effects of dexamethasone.
IL-10+ memory CD4+ T cells are resistant to downregulation
of the IL-2R by dexamethasone
IL-2 plays a central role in supporting the proliferation of T cells
(30, 31), and its production is known to be inhibited by dexa-
methasone (32). Therefore, the contribution of this pathway to the
observed differential effect of dexamethasone on IL-10+ versus
IL-102 cells was investigated next. Cell surface expression of
IL-2R components CD25 (high-affinity IL-2Ra) and CD122
FIGURE 3. Coproduction of IL-10 and proinflammatory cytokines is induced by glucocorticoids in memory CD4+ T cells. Memory CD4+ T cells were stimulated in
the presence of vehicle control or 1 3 1027M dexamethasone (Dex; D27M). On day 5, cells were stimulated for 4 h with PMA and ionomycin prior to performing
intracellular cytokine staining. (A) Representative contour plots. (B) The total (black) percentage of cells producing the indicated cytokine alongside those coexpressing
IL-10+ (red) or the IL-102 counterparts (blue); data assessed by two-way ANOVAwith Sidak multiple comparisons test (IL-10, n = 32; IL-17A, n = 29; IL-17F, n = 7;
IL-22, n = 6; IFN-g, n = 25; IL-4, n = 6; IL-2. n = 19). (C) Representative overlay dot plots identifying which cells within the IL-10/IL-17A plots (black; far left)
coproduced the indicated cytokine in color (IL-17F in yellow, IL-22 in red, IFN-g in blue, IL-4 in green, and IL-2 in orange). *p# 0.05, **p# 0.01, ****p# 0.0001.
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(IL-2Rb) increased upon stimulation over time, and this increase
was inhibited by dexamethasone (Fig. 5A, 5B). Dexamethasone-
treated memory CD4+ T cells also showed lower amounts of
downstream STAT5 phosphorylation as compared with vehicle
control. The cells that had upregulated CD25 proceeded into cell
division regardless of the action of dexamethasone (Fig. 5C).
Moreover, the percentage of CD25+ cells was higher in the IL-10+
cells as compared with IL-102 cells, suggesting that IL-10+ cells
FIGURE 4. IL-17A+ cells and cells coproducing IL-10 are refractory to the suppressive effects of glucocorticoids on cell proliferation. Memory CD4+
T cells were labeled with CellTrace Violet on day 0 and then stimulated in the presence of vehicle control (white) or in the presence of 1 3 1027M
dexamethasone (Dex; gray). On day 5, cells were stimulated for 4 h with PMA and ionomycin prior to performing intracellular cytokine staining.
(A) Representative plots showing expression of cytokines relative to cell proliferation. (B) Cumulative data of the percentage of cells expressing the in-
dicated cytokine within the divided or undivided cell population; data assessed by a two-way ANOVA with Sidak multiple comparisons test. (C) Rep-
resentative histograms showing the proliferation of cells when gating on the indicated cytokine-expressing populations, alongside cumulative data. (D) Data
assessed by a paired t test. IL-17A and IL-10, n = 9; IFN-g and IL-2, n = 7; IL-4, n = 6. *p # 0.05, **p # 0.01, ***p # 0.001, ****p # 0.0001.
The Journal of Immunology 5









are selectively resistant to modulation of CD25 by dexamethasone
(Fig. 5D). This provides a possible explanation for our findings
that IL-10+ memory CD4+ T cells continue to proliferate in the
presence of dexamethasone.
High-dose IL-2 maintains dexamethasone-induced IL-10 while
inhibiting IL-17A in memory CD4+ T cells
In the experiments described above, 50 IU/ml rhIL-2 was routinely
added to all cultures. To further investigate the resistance of IL-10+
cells to downregulation of the IL-2R CD25 and continued prolif-
eration in the presence of dexamethasone, we investigated the con-
tribution of IL-2 to this process. Dexamethasone induction of IL-10
required the addition of rhIL-2, with no dexamethasone-mediated
enhancement of IL-10 observed in the presence of anti–IL-2–
neutralizing mAb because of its suppressive effect on proliferation
(Fig. 6A, 6B). In the absence of dexamethasone, addition of anti–
IL-2 mAb to the cultures led to a consistent decrease in the fre-
quency of cells producing IL-10 and all effector cytokines measured,
with the exception of IL-2, which was shown to be increased as
compared with the vehicle control without IL-2 intervention
(Fig. 6A; data not shown for IFN-g and IL-4). Conversely,
increasing concentrations of rhIL-2 in the absence of dexamethasone
dose dependently increased the frequency of IL-10–producing cells
while reducing that of IL-2–producing cells. Nevertheless, at all
concentrations of IL-2 studied, 50–1000 IU/ml, the addition of
dexamethasone further enhanced the frequency of memory CD4+
FIGURE 5. Glucocorticoids dampen IL-2 signaling in memory CD4+ T cells. Memory CD4+ T cells were stimulated in the presence of vehicle control
(white) or 1 3 1027M dexamethasone (Dex; gray). (A and B) After the indicated length of time, cells were surface stained for CD25 (IL-2Ra; top) and
CD122 (IL-2Rb; middle); for phospho-STAT5 staining, cells were rested for 2 h, stimulated with 5 ng/ml rhIL-2 for 30 min, and then phospho-STAT5
expression was assessed. Shown are representative overlay histograms (A) alongside cumulative data for the mean fluorescence intensity and the percentage
of positive cells [(B); n = 4]. (C) Representative plots showing expression of CD25 by cells relative to their proliferation status (CellTrace Violet) on day 5.
(D) On day 5, cells were stimulated for 4 h with PMA and ionomycin prior to surface CD25 and intracellular cytokine staining (n = 3); shown is the
percentage of CD25+ cells when gating on all cells (left) or the indicated cytokine-expressing populations (n = 3). Data assessed by a two-way ANOVAwith
Sidak multiple comparisons test. *p # 0.05, **p # 0.01, ***p # 0.001.
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T cells producing IL-10 without affecting levels of IL-2
(Fig. 6A, 6B).
Enhancement of the frequency of IL-17A+ T cells by dexamethasone
was also IL-2 dependent, as it was not observed either in the
presence of anti–IL-2 or without addition of exogenous IL-2 to the
cultures (Fig. 6A). In contrast to IL-10, however, the capacity of
dexamethasone to increase IL-17A production was only seen at
the lower concentration of IL-2 studied and was inhibited at the
higher concentrations of IL-2 (500–1000 U/ml). Therefore,
higher-dose rhIL-2 importantly maintained the elevated IL-10
response to dexamethasone while constraining the inductive ef-
fect of dexamethasone on IL-17A. As observed for IL-17A, low-
dose, but not higher concentrations of rhIL-2 were required for
dexamethasone to enhance the frequency of memory CD4+ T cells
coproducing IL-10 and IL-17A (Fig. 6A). Furthermore, when
higher doses of rhIL-2 was added to the cultures, dexamethasone
increased IL-10 production by both dividing and undividing cells
(Fig. 6B, 6C). Thus, our data suggest that IL-2 can independently
upregulate IL-10 in the absence of dexamethasone, and that
dexamethasone further increases IL-10 over and above the effect
of IL-2. Notably, the combination of glucocorticoids and a higher
dose of IL-2 promoted an IL-10+ memory CD4+ T cell population
with minimal coproduction of proinflammatory cytokines.
Discussion
Glucocorticoids are the cornerstone of treatment for patients with
asthma and many other inflammatory conditions, and their clinical
efficacy is linked, in part, to their capacity to induce synthesis of the
anti-inflammatory cytokine IL-10 (9). To further expand our un-
derstanding of glucocorticoid action, we used cells from healthy
individuals who respond to dexamethasone by increases in IL-10
and IL-17A but are devoid of any confounding asthma-associated
defects (7). We show that a major source of glucocorticoid-
induced IL-10 synthesis is CD4+ memory T cells, which are
abundant in tissues such as the lung (33). Glucocorticoids en-
hanced the frequency of IL-10–expressing T cells, an effect that
was particularly marked in T cells coexpressing IL-10 along with
a range of effector, including Th17-associated, cytokines. The
glucocorticoid dexamethasone concurrently increased the fre-
quency of cells producing IL-17A, resulting largely from en-
richment in the frequency of IL-17A+IL-10+ cells. Notably, cells
producing IL-10 and/or IL-17A, including IFN-g+IL-10+, but not
IFN-g+IL-102, cells, were refractory to the antiproliferative ef-
fects of dexamethasone. This glucocorticoid-induced IL-10
production was dependent on IL-2, which, itself, could inde-
pendently upregulate IL-10. Higher doses of rIL-2, while sus-
taining IL-10 production, inhibited the dexamethasone-induced
IL-17A+ response.
IL-10–producing Th17 cells are indicative of the nonpathogenic
Th17 cell population that has been shown to have a critical role
in restraining Th17 cell–mediated inflammatory and autoim-
mune diseases (25–27). This contrasts with proinflammatory
IFN-g+Th17 cells that have been implicated in both murine
(21, 22) and human (23) pathologies. In addition to inducing
IL-10+IL-17+ T cells, we show in this study that dexamethasone
also induced IL-10+IL-22+ cells. Because Th17-associated cyto-
kines play a central role in defense against extracellular infections
at mucosal sites, we propose that, in tissues such as the lung, the
dual capacity of glucocorticoids to both maintain at least certain
antimicrobial defense mechanisms via IL-17A and IL-22, as well
as dampen inflammation via IL-10, is highly desirable. It would,
therefore, be interesting to study the coproduction of these cyto-
kines over the course of a range of diseases in humans; in mice,
IL-22 has been shown to drive the initiation of airway inflam-
mation but act as a negative regulator in established disease (34).
We also observed that dexamethasone selectively enriched a
population of IFN-g+IL-10+ cells, which we hypothesize would
dampen excessive airway inflammation. Indeed, our earlier studies
FIGURE 6. High-dose IL-2 in the context of glucocorticoid induces maximal IL-10 production while inhibiting IL-17A in memory CD4+ T cells.
Memory CD4+ T cells were stimulated with anti-CD3 alone (0 IU/ml rhIL-2), plus 10 mg/ml neutralizing anti-IL-2 (aIL-2) or in the presence of the
indicated concentration of rhIL-2 (50, 500, or 1000 IU/ml) in the presence of vehicle control (white bars) or 1 3 1027M dexamethasone (Dex; gray bars).
On day 5, cells were stimulated for 4 h with PMA and ionomycin prior to performing intracellular cytokine staining. (A) The percentage of cells expressing
the indicated cytokine(s). (B) Representative plots showing expression of IL-10 relative to cell proliferation over the IL-2 titration. (C) The percentage of
IL-10+ cells when gating on the divided (top) or undivided (bottom) cells (n = 6). **p # 0.01, ***p # 0.001, ****p # 0.0001 between control and
dexamethasone.
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in steroid-refractory patients indicate that both IL-17A and IFN-g,
but not IL-10, synthesis are significantly elevated compared with
steroid-sensitive patients (12).
The capacity of dexamethasone to enhance the frequency of cells
coproducing IL-10 with Th17-associated cytokines reflected
preferential outgrowth of this population in culture and was de-
pendent on the presence of the growth factor IL-2. Only the lower
concentration of IL-2 studied promoted the expansion of IL-17A+
or IL-17A+IL-10+ cells. Low-dose IL-2 is required for T cell
proliferation and survival (30, 31), but increased IL-2 signaling
is proposed to impair IL-17A responses as p-STAT5 is reported
to compete with p-STAT3 for binding to the Il17a gene locus
(35, 36). Therefore, the fact that dexamethasone downregulated,
but importantly did not eliminate, expression of IL-2, IL-2Ra1,
IL-2Rb, and p-STAT5 may favor the outgrowth of Th17 cells.
However, we show that higher doses of IL-2 overcame this to
inhibit dexamethasone-induced IL-17A although sustaining
IL-10–producing cells. Hence, our findings provide a novel ap-
proach to promoting nonpathogenic Th17 cells, which coproduce
IL-10. Of note, as well as driving the outgrowth of IL-10+ cells,
the higher concentrations of studied rhIL-2 promoted the expan-
sion of a population of cells that were predominantly negative for
all cytokines assessed (data not shown) and may reflect a central
memory T cell population (37).
The mechanisms by which dexamethasone increases the syn-
thesis of IL-10 and IL-17A are likely to be distinct given the
pleiotropic nature of glucocorticoid actions. The relatively slow
nature of both responses suggests that they are unlikely to be due to
a dexamethasone/GR complex binding directly to target DNA,
although glucocorticoid response elements [consensus motif from
Hocomoco, Jaspar (38)] are located both up- and downstream of
the IL10 promoter. Glucocorticoid response elements are also
found within the vicinity of the IL2, IL2RA, IL2RB, and STAT5
loci, suggesting that dexamethasone may directly influence the
transcription of these genes. Increased production of Th17-
associated cytokines may also be, in part, due to reduced Th1
and Th2 responses, both of which have been shown to reduce
IL-17A production (39, 40). Using the same experimental system,
we previously reported that addition of IL-4 to the culture atten-
uated the IL-17A response (12). Conversely, neutralizing IL-4, but
not IFN-g, in culture increased levels of IL-17A in the control
condition to levels comparable of dexamethasone-treated cells,
which was unaffected by IL-4 blockade (data not shown).
Minimal suppression by glucocorticoids of Th17 cell prolifer-
ation, as shown in this study, has also been observed in murine
in vitro and in vivo systems when compared with Th1 and Th2 cells
(18, 41), and human proinflammatory Th17 cells have been shown
to be refractory to dexamethasone’s suppressive effects on pro-
liferation (23). One potential mechanism for the altered prolifer-
ative response identified in this study is that cells coproducing
IL-17A and IL-10 expressed elevated levels of CD25, which
were refractory to inhibition by dexamethasone, in contrast to
cells not making IL-10, enabling their preferential expansion. In
line with this observation, it has been shown that only a subset of
CD4+ T cells expressing elevated levels of CD25 continue to
proliferate in the presence of dexamethasone, although cytokine
expression was not assessed in that study (42). Our novel findings
show that IL-10+ cells, irrespective of whether they coproduce
proinflammatory cytokines, can maintain IL-2 signaling and pro-
liferate in the presence of glucocorticoids.
Our previous studies identify glucocorticoid-induced IL-17A as
a feature of SR severe asthma (12), but in this study, we address the
underlying mechanisms and single-cell phenotyping. Our data
suggest that aberrant glucocorticoid-driven IL-17A in SR asthma
may be a result of the immune environment in these patients, and,
in particular, low, but not absent, levels of IL-2. Indeed, daily
glucocorticoid therapy might dampen IL-2R expression and sig-
naling to favor Th17 differentiation and/or expansion, particularly
in the setting of weak T cell stimulation, such as during subclin-
ical airways infection with microbes such as Haemophilus, which
is associated with severe asthma (43). To this end, severe asth-
matics were found to have elevated soluble CD25 in circulation
and increased expression by CD4+ T cells, which inversely cor-
related with airway obstruction (44, 45).
Although not studied in asthma, low-dose IL-2 therapy has been
found beneficial in patients with diseases including graft-versus-
host disease, many of whom were receiving glucocorticoids
(46), and hepatitis C virus–induced vasculitis (47). Such beneficial
effects may be due to IL-2 dampening Th17 cells, which is hy-
pothesized to be beneficial in graft-versus-host disease (48).
However, much of the research emphasis has been in describing
the expansion of Foxp3+ Tregs following IL-2 therapy (46, 49, 50).
Coexpression of Foxp3 and IL-10 was not assessed in this study, but
dexamethasone-driven IL-10 was not accompanied by a change in
Foxp3 mRNA or protein expression (data not shown), suggesting
that the cells in this study were not conventional Tregs. This is in
line with both our own and independent reports (51–53) that ob-
serve very low levels of coexpression of Foxp3 and IL-10 protein
in human CD4+ T cells. Our findings, showing that IL-2 increases
IL-10–producing memory CD4+ T cells, may also provide an ex-
planation for the defective IL-10 production, but normal Foxp3
gene expression, in CD4+ T cells from a patient with CD25 defi-
ciency, manifesting as immune dysregulation, polyendocrinopathy,
enteropathy, and X-linked–like syndrome (54).
We have previously shown that vitamin D can restore
dexamethasone-induced IL-10 production in severe asthma
(10, 12), but whether combining IL-2 therapy with glucocorticoids
to further enhance IL-10 production and suppress IL-17A pro-
duction is a pharmacotherapeutic option in severe asthma needs
further consideration. First, IL-17A, and other Th17-associated
cytokines, have both beneficial and harmful actions. Second, one
of the main limitations to IL-2 therapies is the profound differences
in immunologic effects of different IL-2 doses, with proin-
flammatory actions observed at the highest doses. Interestingly,
Sockolosky and colleagues (55) recently published on the genera-
tion of orthogonal IL-2 cytokine receptor complexes that selectively
target cell populations for adoptive cell therapy. Although the study
did not measure its effects on levels of IL-10 and Th17-associated
cytokines, they showed that IL-2, but not the orthogonal IL-2
complex, increased the serum levels of several proinflammatory
cytokines in mice, which is associated with serious side ef-
fects. It would, therefore, be interesting to investigate whether
this may be a mechanism to therapeutically skew responses
toward a single IL-10–producing response, and any impact of
common therapeutic agents, such as glucocorticoids, upon this
process.
In summary, we show that dexamethasone promotes the pref-
erential proliferation of IL-10+ and IL-17A+ memory CD4+
T cells, specifically enriching for populations of cells coproducing
IL-10 and multiple proinflammatory cytokines. Increasing the
concentration of rhIL-2 in the presence of dexamethasone main-
tained elevated levels of IL-10 while reducing the IL-17A
response, which may provide new avenues for the develop-
ment of improved clinical therapies for asthma.
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